ABSTRACT
A dog was hospitalized after accidental overdose and extravasation of doxorubicin. With supportive care and dexrazoxane, systemic toxicity resolved by Day 9 and extravasation injury by Day 36. This case demonstrates that, with treatment, dogs can survive doxorubicin overdose and extravasation. The report also highlights the importance of checking the dose of chemotherapeutic agents and preventing extravasation.
Gestion réussie d'une surdose à la doxorubicine et de l'extravasation chez un chien atteint d'un lymphome. Un chien a été hospitalisé après une surdose accidentelle et l'extravasation de doxorubicine. Avec des soins de soutien et de la dexrazoxane, la toxicité systémique s'est résorbée au Jour 9 et la blessure d'extravasation au Jour 36. Ce cas démontre que, avec un traitement, les chiens peuvent survivre à une surdose de doxorubicine et à l'extravasation. Ce rapport souligne aussi l'importance de la vérification de la dose d'agents chimiothérapeutiques et de la prévention de l'extravasation.(Traduit par Isabelle Vallières).
Subject(s)
Antibiotics, Antineoplastic/adverse effects , Dexrazoxane/therapeutic use , Doxorubicin/adverse effects , Drug Overdose/veterinary , Extravasation of Diagnostic and Therapeutic Materials/veterinary , Animals , Chelating Agents/therapeutic use , Dog Diseases/drug therapy , Dogs , Doxorubicin/therapeutic use , Drug Overdose/drug therapy , Extravasation of Diagnostic and Therapeutic Materials/drug therapy , Female , Lymphoma/drug therapy , Lymphoma/veterinary , Treatment OutcomeABSTRACT
In collaboration with the American College of Veterinary Pathologists.
Subject(s)
Pathology, Veterinary , Veterinarians , Animals , Humans , United StatesABSTRACT
Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty-seven dogs were included; 13 received CCNU-based chemotherapy alone, 18 received surgery and adjuvant CCNU-based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra-thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post-surgical adjuvant chemotherapy.